Actinium Pharmaceuticals, Inc. (ATNM) Presenting at 16th Ann
Actinium Pharmaceuticals, Inc. (ATNM) Presenting at 16th Annual BIO CEO & Investor Conference
Today before the opening bell, Actinium, a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, reported that it will be presenting at the 16th Annual BIO CEO & Investor Conference. The conference is taking place Monday, February 10 to Tuesday, February 11, 2014 at the Waldorf Astoria Hotel in New York City, New York. The company’s President and CEO, Dr. Kaushik J. Dave will be presenting a company overview on Tuesday, February 11, 2014 at 1:30 pm EST.
A telecast of the presentation will be given. Investors and those seeking to watch the presentation are advised to visit the following link for the presentation at 1:30 pm EST on February 11, 2014: https://www.veracast.com/webcasts/bio/ceoinvestor2014/68234189.cfm.
Joining a few minutes ahead of time is advisable, for best viewing results.
Actinium Pharmaceuticals is a New York-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium’s targeted radiotherapy is based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting actinium-225 and bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. The Company’s lead radiopharmaceutical Iomab(TM)-B will be used in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant.
For more information, visit: www.actiniumpharmaceuticals.com
Please read full disclaimers at https://disclaimer.missionir.com